Introduction
Hemangioblastomas are rare benign tumors of the central nervous system (CNS) accounting for about 2% of all intracranialtumors [1] .Surgicalresectionisthestandardofcare. However multiple cerebral hemangioblastomas may require systemic treatment. We report the cases of 2 patients with progressivemultilocularhemangioblastoma,whoweretreated withthevascularendothelialgrowthfactor(VEGF)antibody bevacizumab (Avastin ® , Roche Pharma AG, GrenzachWyhlen,Germany).Theexperimentaltreatmentwasadministered as a compassionate use of the drug after written informedconsentwasobtainedfromthepatientor,incase1, fromthepatient'swifeastheresponsiblerepresentative. fig. 1 B) . A large frontotemporal biopsy confirmed recurrent hemangioblastomaWHOgrade1.AmutationofthevonHippel-Lindau(VHL) gene was ruled out. The patient received antiepileptic treatment with carbamazepine and intravenous dexamethasone (32 mg/day) over the courseof14dayswithoutanyimprovementofhisclinicalcondition.In the absence of evidence-based systemic therapy, we started antiangiogenictreatmentwithbevacizumab(10mg/kg).8daysafterthefirstin-fusion,thepatient'sgeneralconditiongreatlyimproved.Treatmentwas continued at 14-day intervals whereas dexamethasone was tapered off and finally stopped. MRI showed stable disease and reduction of the edema(figs.1CandD).Afterarehabilitationprogram,thepatientwas dischargedinOctober2010.Hehasgainedautonomyinactivitiesofdaily living with a Karnofsky performance score of 80% with occasional seizures.Inconclusion,theclinicalobservationoftherapiddecline before thestartofbevacizumabandremarkableandpromptimprovementofthe patient'sconditionafterthestartofbevacizumab,togetherwithastable course of the disease hereafter, were suggestive of activity of bevacizumab.Thedurablereductionofedemadespitewithdrawalofsteroidsconfirmedtheactivityofbevacizumab.InApril2011,howeverbevacizumab wasstoppedbecauseofclinicalandradiologicalprogression( fig.1E ).In July2011,thepatientisstillalivebutneedshelpwithallactivitiesofdaily living.
Case Report
Case 2 A67-year-oldmanhadasolitaryleftcerebellarcapillaryhemangioblastomaWHOgrade1resectedinAugust1994.InJuly2009,hedevelopeda progressivegaitdisorderwhichledtothediagnosisoflocaltumorrecurrence. He underwent repeat gross total resection in December 2009 in Zurich. No lesions suggestive of VHL disease were identified, and no germlinemutationswerefounduponanalysisofexons1-3oftheVHL gene. Cerebrospinal fluid (CSF) protein was elevated, and spinal MRI showed multiple contrast-enhancing lesions; cranial MRI showed mild leptomeningeal contrast enhancement ( fig. 2 A) . The patient received no further treatment, and the spinal lesions progressed over months ( fig.2B ).Proofofmultiloculardiseasealongthespinalaxiswasobtained bybiopsyof1spinallesioninJuly2010.Thespinalmanifestationofthe disease was reflected by the clinical pattern of the mainly sensory gait disturbanceinvolvingpathologicalsensoryevokedpotentials,severepallhypesthesia,andpositiveRomberg'ssign.Thegaitdisorderfurtherprogressed, leading to severe disability with inability to walk a few meters ducing VEGF [6] [7] [8] . By consequence, hemangioblastomas present histologically with a dense vascular network. Therefore, antiangiogenic treatment seems logical when complete microsurgical resection is impossible. Sunitinib is one of the most frequently used antiangiogenic agents and currently under investigation in a phase II study (ClinicalTrials.gov Identifier:NCT00589784).Sofar,noexperiencewithintravenous bevacizumab has been published; however intravitreal bevacizumabhasbeendescribedinpatientswithVHL-associatedretinalhemangioblastomas [9, 10] .Todate,1openphase 0 study is investigating bevacizumab in hemangioblastomas (ClinicalTrials.gov Identifier: NCT01015300). The 2 patients described here experienced an impressive and long-lasting clinicalbenefit.Theydemonstratedradiologicalstabilization of symptomatic multifocal hemangioblastomas in the brain andspinewithbevacizumab.Thefailuretoinduceobjective remissionsuggeststhatVEGFisnotasurvivalfactorforthe tumorcells,whereastheinductionofstablediseaseindicates thatVEGFmaybeagrowthfactorinthisdisease.Theclinical benefitisdifficulttoexplainbutmaybecausedbyareduction of perfusion and edema and possibly improved perfusion of adjacent brain parenchyma. Possible mechanisms are the knowndecreasesincapillarydensity,microvascularflow,and bloodvesselpermeabilityinresponsetobevacizumab [11, 12] . Weconcludethatbevacizumabmeritsfurtherinvestigationin thiscondition.
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without support. Since surgery, radiation, and chemotherapy were not consideredpromisingtherapeuticoptions,sunitinib,amulti-targetedreceptortyrosinekinaseinhibitor,wasstartedinSeptember2010,basedon theassumptionthatVEGFreceptorsignaltransductionwasrequiredfor tumorcellproliferation.After1weekofsunitinibtreatment(50mg/day), thepatientdevelopedheadachesandepisodesofimpairedconsciousness causedbyCSFflowobstructiontriggeredbyhemorrhageobservedinthe lateralventriclesoncomputedtomography(CT)scan,andconfirmedby lumbar puncture. Sunitinib was stopped since an association with the bleedingcouldnotbeexcluded.Aventriculoperitonealshuntwasplaced, andthepatientrecoveredslowlyoverthecourseofseveralweeks.Still, the follow-up craniospinal MRI in December 2010 showed further progressionofbothintraspinaltumormanifestationsandcontrastenhancement of the cerebral leptomeninges ( fig. 2 C) . After resolution of the bleeding was confirmed by craniospinal MRI and CSF analysis, the patientwasstartedonbevacizumab(10mg/kg,every2weeks).Hisgaitimproved slowly, and almost no signs of ataxia were left by March 2011, after4applicationsofbevacizumab.TheMRIwasvirtuallyunchangedat this time (data not shown). Bevacizumab was continued, and an MRI after 4 months of treatment with bevacizumab (5/2011) again showed stable disease ( fig. 2 D) . To date, the patient walks 4 km every day without any support; his Karnofsky performance status improved from 70to90%.
Discussion
Benign hemangioblastomas of the CNS may occur sporadically, but are mostly seen in association with VHL disease. PatientswithVHLdiseaseusuallyhavelesssevereneurologicalsymptomsandpresentatanearlieragethanpatientswith sporadic lesions [2, 3] . Microsurgical resection is the treatmentofchoice.Forunresectablesymptomatictumors,stereotacticradiosurgerymaybeanalternativeapproachwithless durablelocalcontrol [4] .Despitecompleteexcision,denovo tumorscandevelopyearsaftertheinitialdiagnosis [5] .Hemangioblastomas develop from neoplastic stromal cells pro-
